Men with bone-only oligometastatic prostate cancer (PCa) may benefit from stereotactic body radiotherapy (SBRT), according to investigators.
In a study of 51 patients with 64 bone metastases treated with SBRT, Priyanka H. Patel, MD, of the Royal Marsden NHS Foundation Trust and Institute of Cancer Research in London, and colleagues found that median progression-free survival (PFS) was 3 months and 24 months among patients with castration-resistant and hormone-sensitive cancer, respectively, after a median follow-up of 23 months.
The median PFS of 24 months among the patients with hormone-sensitive cancer is similar to the current evidence base and available published retrospective data on treatment lymph node disease with SBRT, suggesting that oligometastatic disease of bone in patients with PCa may benefit from SBRT, the authors stated.
In addition, 1-, 2-, 3-, and 4-year overall survival rates were 97%, 97%, 92.6%, and 73%, respectively, Dr Patel’s team reported in the World Journal of Urology. No patients experienced grade 3 or 4 toxicities.
“Our data suggest that men with bone-only oligometastatic disease have good outcomes after SBRT to all sites of disease,” the authors concluded.
Dr Patel and colleagues defined oligometastatic disease as the presence of 3 or fewer sites of bone metastases.
The study participants had a median age of 67.5 years. Of the 51 patients, 42 had hormone-sensitive and 9 had castration-resistant cancer. Thirty-nine patients received androgen-deprivation at their primary diagnosis. Four patients died during follow-up, and all of them had castration-resistant disease at the time of SBRT.
Patel PH, Chaw CL, Tree AC, et al. Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer. World J Urol. 2019. doi: 10.1007/s00345-019-02873-w